Can you tell me about the latest drug launch by Zydus Cadila for cholesterol?

Zydus Lifesciences has pioneered the launch of a new class of the “Bemdac” drug in India. The purpose of this drug is to treat uncontrolled LDL cholesterol. People who have uncontrolled levels of LDL cholesterol are vulnerable to a range of cardiovascular diseases. Bemdac will go a long way in giving them relief with a generic drug that is more effective and at the same time is also priced more reasonably.

The potential market in India is huge, which is becoming the cholesterol capital of the world. There are approximately about 112 million adults in India suffering from LDL cholesterol, and nearly 50% of these people are intolerant to the existing statin therapy. Bemdac enriches the cardiac care portfolio of Zydus, which includes Atorva, Clopitorva, Zyrova and Pivasta and Bemdac enriches this list. Zydus was formerly known as Cadila Healthcare.